Outcomes of natalizumab treatment within 3 years of relapsing-remitting multiple sclerosis diagnosis: a prespecified 2-year interim analysis of STRIVE von Perumal, Jai, Fox, Robert J, Balabanov, Roumen, Balcer, Laura J, Galetta, Steven, Makh, Shavy, Santra, Sourav, Hotermans, Christophe, Lee, Lily

Volltext

Randomized phase I clinical trial of anti–α‐synuclein antibody BIIB054 von Brys, Miroslaw, Fanning, Laura, Hung, Serena, Ellenbogen, Aaron, Penner, Natalia, Yang, Minhua, Welch, Mackenzie, Koenig, Erica, David, Eric, Fox, Tara, Makh, Shavy, Aldred, Jason, Goodman, Ira, Pepinsky, Blake, Liu, YuTing, Graham, Danielle, Weihofen, Andreas, Cedarbaum, Jesse M.

Volltext

Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of Anti-Alpha-Synuclein Antibody BIIB054 in Patients with Parkinson’s Disease (S26.001) von Brys, Miroslaw, Ellenbogen, Aaron, Fanning, Laura, Penner, Natasha, Yang, Minhua, Welch, Mackenzie, Koenig, Erica, David, Eric, Fox, Tara, Makh, Shavy, Aldred, Jason, Goodman, Ira, Graham, Danielle, Weihofen, Andreas, Cedarbaum, Jesse

Volltext

A distinct subset of chemokines, induced in colonic epithelium by IL-1β dominates the mucosal chemokine response in ulcerative colitis von Puleston, Jo, Cooper, Mike, Murch, Simon, Shavy, Makh, Paul, Ashwood, Bingham, Alistair, Green, Heather, Moss, Pat, Dhillon, Amar, Gelinas, Richard, Pounder, Roy, Platt, Adam

Volltext

Outcomes of natalizumab treatment within 3 years of relapsing-remitting multiple sclerosis diagnosis: a prespecified 2-year interim analysis of STRIVE von Perumal, Jai, Fox, Robert J, Balabanov, Roumen, Balcer, Laura J, Galetta, Steven, Makh, Shavy, Santra, Sourav, Hotermans, Christophe, Lee, Lily

Volltext